Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
New breast cancer study findings have been reported from P. Biron et al
May 15th, 2008
"Pegase 03 is a multicenter prospective randomized phase III trial evaluating the impact of first-line high-dose chemotherapy (HDC) with stem cell support on overall survival (OS), disease-free survival (DFS) and response rate in 308 patients with histologically proven metastatic breast cancer responding to induction therapy. Eligible patients received four induction cycles with FEC 100 (5-fluorouracil 500mg/m(2), epirubicin 100 mg/m(2), cyclophosphamide 500 mg/m(2))," scientists writing in the journal Bone Marrow Transplantation report. "Patients with objective response (N=179) were randomized to one cycle of HDC (cyclophosphamide 6000 mg/m2 and thiotepa 800...
Source: Women's Health Weekly (2008-05-15)
|
